AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 71 min read$PMN

Kaplan Johanne purchased $30K of PMN

Kaplan Johanne (Chief Development Officer) purchased 2,280 shares of ProMIS Neurosciences Inc. (PMN) at $13.30 on 2026-08-05.

Original reporting
SEC EDGAR · Kaplan Johanne
Published Aug 7, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PMN
Bullish
low confidence
Mentioned
$PMN
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PMNBullishLow
01

Why it matters

The newest fact is the specific open-market purchase details by the Chief Development Officer, which may modestly influence sentiment but does not provide new business or financial information.

02

Market read

Traders may note the insider buy as a small positive datapoint, but it is unlikely to drive a material repricing without corroborating fundamentals.

03

What to watch

The filing does not state motivations, and the absence of a 10b5-1 plan does not automatically imply conviction; it only indicates the trade was not under a pre-set plan.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-07, transaction dated 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for ProMIS Neurosciences Inc.

Company-level read

Ticker impact

$PMNBullishLow confidence
Context

ProMIS Neurosciences insider Form 4 shows CDO Kaplan Johanne bought 2,280 shares at $13.30 on 2026-08-05, totaling $30,324.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and should fade unless followed by additional disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but the disclosed size is modest and there is no accompanying operational or financial update.

Market effects

Sector

No clear sector read-through from a single, small insider purchase.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buying can be routine or opportunistic and may not reflect a change in company fundamentals, especially without a broader pattern of purchases.

Key entities

  • issuer
    ProMIS Neurosciences Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Kaplan Johanne

    Chief Development Officer who purchased 2,280 shares at $13.30 on 2026-08-05.

Read at source← All news

Related articles

JUL 29
$TRIBMed

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

rttnews.com7 min
JUL 28
$PMNMed

Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data

Promis Neurosciences (NASDAQ:PMN) reported interim Phase 1b safety data for PMN310 in Alzheimer’s. As of July 22, there were no ARIA-E cases in the blinded safety population and no treatment-related serious adverse events. Total ARIA was 4.4% (mild, asymptomatic ARIA-H). Biomarkers showed declines in plasma p-tau217 and CSF MTBR-tau243. Dosing runs to Dec 2026; unblinding expected early 2027.

finance.yahoo.com5 min
JUL 28
$PMNMedAI 8/10

Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study - ProMI

ProMIS Neurosciences reported a blinded interim safety analysis of PMN310 in an early Alzheimer’s study with 136 patients. It said no ARIA-E cases occurred by the cutoff, total ARIA incidence was 4.4% and limited to mild, asymptomatic ARIA-H. No treatment-related serious adverse events or discontinuations were reported, including in APOE4 carriers. Unblinded 12-month topline results are expected in Q1 2027.

benzinga.com5 min
JUL 28
$PMNMedAI 8/10

Why is ProMIS Neurosciences stock surging today? By Investing.com

ProMIS Neurosciences (PMN) shares rose about 16% pre-open after the company reported blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial of PMN310. In 136 patients, there were zero ARIA-E cases, 4.4% total ARIA incidence, and no treatment-related serious adverse events. Chardan started coverage with a Buy and $20 target.

investing.com4 min
JUL 28
$PMNMedAI 8/10

ProMIS Neurosciences Inc.: ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial

ProMIS Neurosciences (Nasdaq: PMN) reported blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial of PMN310 in 136 Alzheimer’s patients. As of the cutoff, no ARIA-E occurred and total ARIA was 4.4% (mild, asymptomatic ARIA-H only). Early biomarker shifts in pTau217 and CSF MTBR-tau243 were reported. Unblinded 12-month topline data are expected in Q1 2027.

finanznachrichten.de5 min